Amedisys Inc (AMED) Receives Buy Rating from Oppenheimer Holdings, Inc.
Amedisys Inc (NASDAQ:AMED)‘s stock had its “buy” rating restated by equities research analysts at Oppenheimer Holdings, Inc. in a research report issued on Friday. They currently have a $60.00 price objective on the health services provider’s stock. Oppenheimer Holdings, Inc.’s price objective indicates a potential upside of 15.32% from the stock’s current price.
AMED has been the topic of several other reports. Mizuho lowered shares of Amedisys from a “buy” rating to a “neutral” rating and set a $50.00 price objective on the stock. in a research report on Wednesday, July 26th. Bank of America Corporation assumed coverage on shares of Amedisys in a research report on Monday, August 21st. They issued a “neutral” rating and a $55.00 price objective on the stock. BidaskClub raised shares of Amedisys from a “sell” rating to a “hold” rating in a research report on Friday, August 11th. Finally, Royal Bank Of Canada reissued a “hold” rating and issued a $56.00 price objective on shares of Amedisys in a research report on Monday, June 5th. Seven research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $56.44.
Amedisys (AMED) traded down 1.42% on Friday, hitting $52.03. 418,479 shares of the stock traded hands. The firm’s 50 day moving average is $49.87 and its 200 day moving average is $54.84. The stock has a market cap of $1.76 billion, a price-to-earnings ratio of 44.47 and a beta of 0.84. Amedisys has a 52 week low of $34.58 and a 52 week high of $65.91.
Amedisys (NASDAQ:AMED) last issued its quarterly earnings data on Wednesday, July 26th. The health services provider reported $0.62 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.50 by $0.12. The company had revenue of $378.80 million for the quarter, compared to analyst estimates of $380.80 million. Amedisys had a net margin of 2.70% and a return on equity of 13.71%. The company’s revenue was up 5.0% on a year-over-year basis. During the same period in the prior year, the firm earned $0.42 earnings per share. Equities analysts anticipate that Amedisys will post $2.21 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: This news story was posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another website, it was stolen and republished in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/09/15/amedisys-inc-amed-receives-buy-rating-from-oppenheimer-holdings-inc.html.
In other Amedisys news, Director Bruce D. Perkins purchased 2,000 shares of the stock in a transaction that occurred on Thursday, August 3rd. The shares were acquired at an average cost of $46.60 per share, with a total value of $93,200.00. Following the completion of the transaction, the director now owns 15,825 shares in the company, valued at $737,445. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider David B. Pearce sold 1,000 shares of the firm’s stock in a transaction dated Tuesday, August 8th. The stock was sold at an average price of $50.00, for a total transaction of $50,000.00. Following the transaction, the insider now directly owns 10,488 shares in the company, valued at $524,400. The disclosure for this sale can be found here. 2.80% of the stock is currently owned by company insiders.
A number of large investors have recently added to or reduced their stakes in the stock. Federated Investors Inc. PA increased its position in Amedisys by 2.3% during the second quarter. Federated Investors Inc. PA now owns 1,929 shares of the health services provider’s stock worth $122,000 after acquiring an additional 44 shares during the period. State Board of Administration of Florida Retirement System increased its position in Amedisys by 0.5% during the second quarter. State Board of Administration of Florida Retirement System now owns 19,658 shares of the health services provider’s stock worth $1,235,000 after acquiring an additional 93 shares during the period. Suntrust Banks Inc. increased its position in Amedisys by 2.0% during the first quarter. Suntrust Banks Inc. now owns 5,465 shares of the health services provider’s stock worth $279,000 after acquiring an additional 107 shares during the period. Municipal Employees Retirement System of Michigan increased its position in Amedisys by 1.8% during the first quarter. Municipal Employees Retirement System of Michigan now owns 6,370 shares of the health services provider’s stock worth $325,000 after acquiring an additional 110 shares during the period. Finally, Arizona State Retirement System grew its stake in Amedisys by 1.4% during the first quarter. Arizona State Retirement System now owns 14,550 shares of the health services provider’s stock worth $743,000 after buying an additional 200 shares in the last quarter. 96.80% of the stock is currently owned by institutional investors and hedge funds.
Amedisys Company Profile
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with MarketBeat.com's FREE daily email newsletter.